Save your place

Sign in to WhoBought

Please try again later.

Vanda Pharmaceuticals Inc. (VNDA) institutional ownership

Market cap$334M SectorHealthcare
Funds holding · Q1 2026
172
reported VNDA position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
107 buyers · 65 sellers

Vanda Pharmaceuticals Inc. (VNDA) price and institutional activity

Dates

Q1 2026

$0 bought by 107 investors
State StreetAQR Capital Management LLC +105 more
$0 sold by 65 investors
Two Sigma Advisers, LPAcadian Asset Management LLC +63 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

Vanda Pharmaceuticals Inc. (VNDA) institutional activity · 172

Investor Type Est. change Change Δ Own Date
State Street · Added
Change +1.8M Date Q1 2026
State Street Added· Q1 2026 +1.8M Q1 2026
Two Sigma Advisers, LP · Exited
Change −1.0M Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −1.0M −100.0% Q1 2026
AQR Capital Management LLC · Added
Change +977K Date Q1 2026
AQR Capital Management LLC Added· Q1 2026 +977K Q1 2026
Aigh Capital Management LLC · Added
Change +752K Date Q1 2026
Aigh Capital Management LLC Added· Q1 2026 +752K Q1 2026
Citadel Advisors LLC New· Q1 2026 +633K Q1 2026
Acadian Asset Management LLC · Reduced
Change −615K Date Q1 2026
Acadian Asset Management LLC Reduced· Q1 2026 −615K Q1 2026
Marshall Wace, LLP · New
Change +596K Date Q1 2026
Marshall Wace, LLP New· Q1 2026 +596K Q1 2026
BlackRock · Reduced
Change −498K Date Q1 2026
BlackRock Reduced· Q1 2026 −498K Q1 2026
Jacobs Levy Equity Management, Inc · Added
Change +460K Date Q1 2026
Jacobs Levy Equity Management, Inc Added· Q1 2026 +460K Q1 2026
Goldman Sachs Group Inc · Added
Change +430K Date Q1 2026
Goldman Sachs Group Inc Added· Q1 2026 +430K Q1 2026
Two Sigma Investments, LP · Added
Change +419K Δ Own +42.8% Date Q1 2026
Two Sigma Investments, LP Added· Q1 2026 +419K +42.8% Q1 2026
Renaissance Technologies LLC Added· Q1 2026 +379K +11.2% Q1 2026
Connor, Clark & Lunn Investment Management Ltd. · Reduced
Change −367K Date Q1 2026
Connor, Clark & Lunn Investment Management Ltd. Reduced· Q1 2026 −367K Q1 2026
Dimensional · Reduced
Change −347K Date Q1 2026
Dimensional Reduced· Q1 2026 −347K Q1 2026
Jump Financial, LLC · Reduced
Change −275K Date Q1 2026
Jump Financial, LLC Reduced· Q1 2026 −275K Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 172

Famous investor activity in Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. (VNDA) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
McGuire Daniel Patrick · Officer Grant (A) 80K
Owned 110K Trade date Jun 4, 2026 Filed date Jun 8, 2026
McGuire Daniel Patrick Officer Grant (A) 80K 110K Jun 4, 2026 Jun 8, 2026
Chrousos Phaedra · Director Grant (A) 42K
Owned 165K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Chrousos Phaedra Director Grant (A) 42K 165K Jun 4, 2026 Jun 8, 2026
Duncan Charles Cliff · Director Grant (A) 42K
Owned 99K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Duncan Charles Cliff Director Grant (A) 42K 99K Jun 4, 2026 Jun 8, 2026
Dugan Richard W. · Director Grant (A) 42K
Owned 219K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Dugan Richard W. Director Grant (A) 42K 219K Jun 4, 2026 Jun 8, 2026
Ward Anne Sempowski · Director Grant (A) 42K
Owned 161K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Ward Anne Sempowski Director Grant (A) 42K 161K Jun 4, 2026 Jun 8, 2026
Honore Tage · Director Grant (A) 42K
Owned 135K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Honore Tage Director Grant (A) 42K 135K Jun 4, 2026 Jun 8, 2026
Mitchell Stephen Ray · Director Grant (A) 42K
Owned 113K Trade date Jun 4, 2026 Filed date Jun 8, 2026
Mitchell Stephen Ray Director Grant (A) 42K 113K Jun 4, 2026 Jun 8, 2026
Mitchell Stephen Ray · Director Gift (G) -26K
Owned 71K Trade date May 18, 2026 Filed date May 20, 2026
Mitchell Stephen Ray Director Gift (G) -26K 71K May 18, 2026 May 20, 2026
Duncan Charles Cliff · Director Grant (A) 57K
Owned 57K Trade date Apr 22, 2026 Filed date Apr 24, 2026
Duncan Charles Cliff Director Grant (A) 57K 57K Apr 22, 2026 Apr 24, 2026
Williams Timothy · Officer Sell −$351K
Price $8.27 Qty −42K Owned 377K Trade date Mar 2, 2026 Filed date Mar 4, 2026
Williams Timothy Officer Sell $8.27 −42K −$351K 377K Mar 2, 2026 Mar 4, 2026
Moran Kevin Patrick · Officer Sell −$351K
Price $8.27 Qty −42K Owned 411K Trade date Mar 2, 2026 Filed date Mar 4, 2026
Moran Kevin Patrick Officer Sell $8.27 −42K −$351K 411K Mar 2, 2026 Mar 4, 2026
Wijkstrom Joakim · Officer Sell −$255K
Price $8.27 Qty −31K Owned 333K Trade date Mar 2, 2026 Filed date Mar 4, 2026
Wijkstrom Joakim Officer Sell $8.27 −31K −$255K 333K Mar 2, 2026 Mar 4, 2026
Polymeropoulos Mihael Hristos · Director, Officer, Other Sell −$1.3M
Price $8.17 Qty −156K Owned 2.7M Trade date Mar 2, 2026 Filed date Mar 4, 2026
Polymeropoulos Mihael Hristos Director, Officer, Other Sell $8.17 −156K −$1.3M 2.7M Mar 2, 2026 Mar 4, 2026
Birznieks Gunther · Officer Sell −$351K
Price $8.27 Qty −42K Owned 494K Trade date Mar 2, 2026 Filed date Mar 4, 2026
Birznieks Gunther Officer Sell $8.27 −42K −$351K 494K Mar 2, 2026 Mar 4, 2026
Honore Tage · Director Sell −$241K
Price $8.03 Qty −30K Owned 93K Trade date Feb 23, 2026 Filed date Feb 24, 2026
Honore Tage Director Sell $8.03 −30K −$241K 93K Feb 23, 2026 Feb 24, 2026
15 of 21
15 of 21 Sign in to continue to older insider transactions.

Vanda Pharmaceuticals Inc. (VNDA) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
BlackRock Inc. 8.3M
% of shares outstanding 14.5% Filing date Jan 23, 2024
BlackRock Inc. 8.3M 14.5% Jan 23, 2024
Renaissance Technologies LLC 3.7M
% of shares outstanding 6.4% Filing date Feb 13, 2024
Renaissance Technologies LLC 3.7M 6.4% Feb 13, 2024
Vanguard Group Inc 3.5M
% of shares outstanding 6.0% Filing date Feb 13, 2024
Vanguard Group Inc 3.5M 6.0% Feb 13, 2024
State Street Corporation 3.0M
% of shares outstanding 5.1% Filing date May 12, 2026
State Street Corporation 3.0M 5.1% May 12, 2026
BlackRock Portfolio Management LLC 2.5M
% of shares outstanding 4.2% Filing date Apr 29, 2026
BlackRock Portfolio Management LLC 2.5M 4.2% Apr 29, 2026
Dimensional Fund Advisors LP 2.0M
% of shares outstanding 3.4% Filing date Feb 9, 2024
Dimensional Fund Advisors LP 2.0M 3.4% Feb 9, 2024
Macquarie Group Ltd 1.3M
% of shares outstanding 2.3% Filing date Feb 14, 2023
Macquarie Group Ltd 1.3M 2.3% Feb 14, 2023
Palo Alto Investors LP 1.1M
% of shares outstanding 1.4% Filing date Feb 14, 2023
Palo Alto Investors LP 1.1M 1.4% Feb 14, 2023
8 of 9

Vanda Pharmaceuticals Inc. (VNDA) ownership FAQ

Who owns VNDA?

172 reporting institutions disclosed VNDA position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.